mRECIST for systemic therapies: More evidence is required before recommendations can be made.
Medical Oncology, Centre Eugène Marquis, Rennes, France. Electronic address: j.edeline@rennes.unicancer.fr.
Julien
J
Edeline
Department of Molecular and Clinical Cancer Medicine, University of Liverpool, and The Clatterbridge Cancer Centre NHS Foundation Trust, United Kingdom.
Daniel
D
Palmer
CHU Hôpital Saint André, Bordeaux, France.
Jean-Frédéric
JF
Blanc
Medical Oncology, Centre Eugène Marquis, Rennes, France.
Boris
B
Campillo-Gimenez
Groupement Hospitalier Lyon Nord, Hepatology Unit, Lyon, France.
Philippe
P
Merle
Royal Free Hospital, London, United Kingdom; UCL Cancer Institute, University College London, London, United Kingdom.
Tim
T
Meyer
D015415:Biomarkers; D006528:Carcinoma, Hepatocellular; D016461:Chemoembolization, Therapeutic; D006801:Humans; D008113:Liver Neoplasms; D016896:Treatment Outcome
D015415:Biomarkers